PTPRC and gastric cancer: To further investigate whether CD45+CD33lowCD11bdim myeloid cells were a clinically relevant biomarker of GC, we staged GC patients according to the TNM classification system, and found that peripheral blood CD45+CD33lowCD11bdim myeloid cell frequency was positively associated with advanced stage GC progression (Fig. 6a).